[{"id":"296c96e7-b22e-4040-a519-2e7ecf12e1f7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03147378","created_at":"2021-10-19T13:55:36.804Z","updated_at":"2024-07-02T16:36:22.779Z","phase":"Phase 1","brief_title":"Food Effect Study of ModraDoc006 in Combination With Ritonavir","source_id_and_acronym":"NCT03147378","lead_sponsor":"Modra Pharmaceuticals","biomarkers":" ABCB1 • ABCC2","pipe":"","alterations":" ","tags":["ABCB1 • ABCC2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel oral/ritonavir (ModraDoc006/r)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 05/10/2017","start_date":" 05/10/2017","primary_txt":" Primary completion: 04/04/2018","primary_completion_date":" 04/04/2018","study_txt":" Completion: 04/04/2018","study_completion_date":" 04/04/2018","last_update_posted":"2021-10-19"},{"id":"dd1a6cf8-4d0d-4d05-81ed-0f9c70167f2c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03890744","created_at":"2021-01-18T19:09:46.227Z","updated_at":"2024-07-02T16:36:22.803Z","phase":"Phase 2a","brief_title":"ModraDoc006/r in Patients With Breast Cancer","source_id_and_acronym":"NCT03890744","lead_sponsor":"Modra Pharmaceuticals","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel oral/ritonavir (ModraDoc006/r)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 01/30/2019","start_date":" 01/30/2019","primary_txt":" Primary completion: 02/13/2020","primary_completion_date":" 02/13/2020","study_txt":" Completion: 11/09/2020","study_completion_date":" 11/09/2020","last_update_posted":"2021-10-19"}]